Abstract: The invention relates to a method for the production of a time-stable, solid appetizing composition and to the use thereof, said composition comprising at least one active substance which is introduced in the final production step, by adding same to the already formed mixture of other components at ambient temperature, without the use of water or heat. The composition is intended for use as a drug, a nutraceutical or a food supplement for oral administration to mammals, except humans, in particular for pets such as dogs, cats or horses. The stable solid composition is obtained by compressing the mixture using a press for compressing formulations having a high fat content.

Abstract: An edible composition comprising starch and cellulose ether particles, wherein the cellulose ether particles have a median Equivalent Projected Circle Diameter (EQPC 50,3) of up to 110 micrometers and a Crystallinity Index, CI, of not more than 0.43, wherein CI=(I200?1am)/I200> where I200 is the intensity of the highest peak in the X-ray diffraction spectral pattern of the cellulose ether particles and Iam is the intensity of the valley between the highest peak I200 and the higher of the one or two peaks adjacent to the highest peak, is useful for preparing battered foods of reduced oil and/or fat uptake when fried.

Abstract: An edible composition comprising starch and cellulose ether particles, wherein the cellulose ether particles have a ratio M3.0/M2.0 of not more than 200 micrometers, wherein M3.0 is the number volume mean and M2.0 is the number surface area mean of the cellulose ether particles, and/or wherein the cellulose ether particles have a volume fraction of fibrous particles of no more than 40%, is useful for preparing a batter by mixing the edible composition with water. The batter is contacted with a food to prepare a battered food. The battered foods have a reduced oil and/or fat uptake when fried, as compared to fried non-battered food.

Abstract: A rail vehicle includes a chassis, a vehicle structure and a support unit disposed at the end face of the rail vehicle. The vehicle is comparatively lightweight and economical and can also advantageously perform other tasks in addition to supporting a track reamer. The support unit includes a plateau section which is part of the vehicle structure and includes a climbing protection device on its end face and a track reamer holder for supporting a track reamer. The track reamer holder is disposed below the plateau section and is rigidly secured thereto.

Abstract: The present invention is related to a formulation comprising Hedera helix, Pelargonium sidoides, and Zingiber officinale extracts to be used in the treatment, prevention of various respiratory diseases or alleviation and/or elimination of symptoms thereof and a method for preparing said formulation.

Abstract: A method of inhibiting inflammation with milk oligosaccharides or glycoconjugates containing the oligosaccharides.

Abstract: Heat-treated liquid enteral nutritional composition with a low monovalent metal ion content are provided that contain micellar casein and optionally caseinate, and in which the total amount of monovalent metal ions is less than 25 mg/g of protein. Also, heat-treated liquid enteral nutritional compositions are disclosed comprising 10 to 20 g of protein per 100 ml of the composition, in which all or a major part of said protein comprises micellar casein. Also, a method is disclosed for producing the composition according to the invention, comprising a step wherein an aqueous protein solution in which all or a major part of said protein comprises micellar casein, is subjected to an evaporation step.

Abstract: The present invention relates generally to a methods of treating ear infections and clearing excess fluid from Eustachian tubes.

Abstract: A dietary product for preventing cardiometabolic risk in humans, in particular for reducing visceral fat and deep subcutaneous fat, includes in particular a mixture of: a whey hydrolysate having a molecular weight of between 200 and 10,000 daltons, an isolate and/or concentrate of whey, and calcium caseinate.

Abstract: It is an object of the present invention to provide a destination estimating system and a destination estimating method capable of estimating a destination with a high degree of accuracy even when a user uses a detour or stops off somewhere.

Abstract: The invention relates to pharmaceutical compositions for direct systemic introduction, are also known as DSI pharmaceutical compositions, for used as human veterinary pharmaceutical compositions. In one embodiment, the invention relates to a pharmaceutical composition for direct system introduction comprising bovine gelatin, mannitol, an optional surfactant, an optional flavorant, and an active pharmaceutical ingredient. A DSI pharmaceutical composition of the invention has a disintegration time of 7 seconds or less in deionized water maintained at 37.0° C.±0.5° C. The invention also relates to a method of delivering an active pharmaceutical ingredient to an animal comprising the step of placing a DSI pharmaceutical composition of the invention into a mucosal cavity of an animal to be treated with the active pharmaceutical ingredient and to the corresponding methods of treatment.

Abstract: The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.

Abstract: The invention relates to a ready-to-drink tea beverage comprising water, tea solids, protein and primary cell wall material. The primary cell wall material is derived from plant parenchymal tissue and has been treated to contain at least partially disentangled cellulose microfibrils. The invention further relates to a method for preparing said ready-to-drink tea beverage comprising the steps of •—mixing at least part of the water and primary cell wall material; and •—subjecting this mixture to mechanical energy and/or cavitation.

Abstract: An oral pharmaceutical composition of isotretinoin and a carrier substrate, having isotretinoin in the form of gel, dispersion, solution or emulsion, which is absorbed onto the carrier substrate to form solid particles, powder, or granules. The oral pharmaceutical composition has enhanced bioavailability. A process is used for preparing the oral composition.

Abstract: The present invention belongs to the fields of pharmacology, medicine and medicinal chemistry. The present invention provides novel pharmaceutical compositions composed of solid nanoparticles dispersed in aqueous medium of substantially water insoluble pharmaceutical substances such as docetaxel with reduced Ostwald ripening.

Abstract: An edible animal medicine container for delivering medicine or other ingestible material, contained therein, to an animal, includes first and second edible housing shells. The first shell includes a first peripheral ledge, surrounding a first central hollow, and a first interlocking feature extending therefrom. The second shell includes a second peripheral ledge, surrounding a second central hollow, and a second interlocking feature extending into, and at least partially defined by, the second peripheral ledge. The second shell is positionable relative to, and connectable to, the first shell to define an interior in which the ingestible material may be disposed. In such connected state the first interlocking feature is seated and frictionally held within the second interlocking feature of the second edible housing shell so as to retain the first and second shells together and thereby retain the ingestible material within the interior until ingested by an animal.

Abstract: Nutrient compositions comprising botanical extracts and an omega 3 fatty acid as well as methods of their use for treating, inter alia, autism or apraxia and/or ameliorating one or more symptoms thereof are disclosed. The use of such compositions for enhancing cognitive function and/or one or more aspects thereof, or for treating stroke or seizures and/or ameliorating one or more symptoms thereof are also disclosed.

Abstract: A pre-filled syringe storing an anesthetic is disclosed. The pre-filled syringe includes a container configured to store a liquid anesthetic solution. The liquid anesthetic solution includes an anesthetic, water, and a solvent. The container is made of a plastic that is inert to the anesthetic. The pre-filled syringe also includes a plunger made of siliconized bromobutyl rubber that is inert to the anesthetic and a rubber stopper made of siliconized bromobutyl rubber that is inert to the anesthetic. The plunger and the rubber stopper seal the container configured to store the liquid anesthetic solution.

Abstract: A dietary supplement composition and associated method of use has the composition formulated in a therapeutic amount to treat and alleviate symptoms of joint pain in a person having joint pain. The composition includes astaxanthin and microbial fermented, low molecular weight hyaluronic acid or sodium hyaluronate (hyaluronan). The composition also includes at least one of a phospholipid, glycolipid, and sphingolipid. It is formulated into an oral dosage form and the astaxanthin is 0.1 to 15 percent by weight of the at least one phospholipid, glycolipid, and sphingolipid.

Abstract: Methods of producing high purity palmitoleic acid esters from natural oils are disclosed. The natural oils may comprise plant oil, nut oil, microalgae oil, and fish oil. The methods of processing the natural oil comprise transesterification with ethanol as the reacting solvent to produce ethyl esters. Methods of producing a high purity fraction of Omega-3, 6, & 9 fatty acid esters from natural oils are also disclosed. The high purity fatty acid esters may be used in nutrition, cosmetic, and nutraceutical products.

Abstract: [Problem] To provide a phospholipid ?-linolenic acid composition of consistent quality and having a stable supply of source material, with focus on Torula yeast, which is edible and recognized as safe, in order to resolve issues with omega 3 sources. [Means for Solving the Problem] As a result of intensive study to resolve the above-noted issues, the inventors of the present invention have discovered that a phospholipid ?-linolenic acid composition can be obtained using residue of yeast extract extracted from Torula yeast (Candida utilis), for example, which is currently produced in large quantities for application in foods, and so arrived at the present invention.

Abstract: Sperm mobility and impregnation of an oocyte is enhanced by placing sperm in an aqueous solution of phospholipids prior to in vitro fertilization or artificial insemination. The aqueous phospholipid solution can also be used during storage or cryopreservation of the sperm. Also, the motility of sperm produced or ejaculated and the environment into which it is placed is enhanced my ingestion of the phospholipid composition by the male or female, or a vaginal placement of compositions containing the phospholipids.

Abstract: This invention provides a solid oral formulation including a tablet core surrounded by an iron sugar overcoat so that the iron sugar overcoat makes at least some elemental iron content available for gastrointestinal absorption relative to the tablet core while counteracting at least some of the constipation associated with oral iron consumption, and further includes methods of administering the solid oral formulation.

Abstract: This invention relates to a method of improving CNS maturation in an infant by administering a mixture of natural tocopherols, wherein the composition contains an optimum tocopherol profile similar to that found in human breast milk, and can encompass a tocopherol profile from early stage to transitional to mature human breast milk. For ease of administration and maximized efficacy, the optimized mixture of natural tocopherols are typically delivered in an oral dosage form with a limited level of non-RRR alpha-tocopherols to maximize efficacy of the RRR alpha-tocopherol on stimulating post-natal CNS development.

Abstract: The invention provides a composition the prevention and treatment of cardiovascular disease, wherein said composition compounds obtained from palm oil mill effluents, in particular from vegetative liquor from the milling of palm oil fruit.

Abstract: Embodiments of the present invention are directed to methods, apparatus and articles of manufacture that feature omega-3 fatty acids co-processed with flavonoid and lipophilic antioxidants for improved stability.

Abstract: A method of delivering a daily dose of hydroxycitric acid in the form of a salt as a single bolus that is as effective or more so than the same amount of active delivered via two or three administrations (b.i.d. or t.i.d.) using current delivery modalities. The method reduces the rate of occurrence of common adverse events with hydroxycitric acid salts, and reduces the occurrence of reverse effects on diets high in fat and/or alcohol. The method improves the uptake of the active compound thereby reducing the dose required.

Abstract: The invention described herein provides a preparation comprising a non-mammalian derived mixture of serine glycerophospholipid conjugates with a specific content and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and EPA which depend on utilizing different sources of lipids, and uses of such preparations.

Abstract: A solid oral pharmaceutical composition for delivery of a pharmaceutically acceptable active ingredient to an animal where the composition comprises an isoxazoline compound, a solvent and an excipient, a process for the manufacture of such solid oral pharmaceutical composition and a method of controlling a parasite infection administering such solid oral pharmaceutical composition.

Abstract: The present invention provides a low dose oral pharmaceutical composition of isotretinoin having reduced food effect, in particular no food effect. The present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention.

Abstract: Provided are beverage compositions comprising a urine citrate increasing component and a urine oxalate reducing component. The beverage compositions may be provided in a ready-to-drink form or may be provided in a concentrate form. Also provided are kits comprising the beverage compositions and methods for treating various conditions using the beverage compositions.

Abstract: Methods and formulations for increasing the water solubility and/or bioavailability of a lipophilic natural compounds is disclosed. The formulations may be employed to make liquid filled capsules or clear and stable beverages containing therapeutic amounts of the active ingredients, for example.

Abstract: A method of manufacturing a resorbable, macroporous bioactive glass scaffold comprising approximately 24-45% CaO, 34-50% SiO2, 0-25% Na2O, 5-17% P2O5, 0-5% MgO and 0-1% CaF2 by mass percent, produced by mixing with pore forming agents and specified heat treatments.

Abstract: The present invention provides a composition comprising HMB and Vitamin D. Methods of administering HMB and Vitamin D to an animal are also described. Vitamin D and HMB are administered to increase muscle mass, strength, and functionality. The combination of Vitamin D and HMB together has a synergistic effect, which results in a surprising and unexpected level of improvement in muscle mass, strength and functionality.

Abstract: Described herein are methods, compositions, systems, and kits that effectively deliver a laxative to a patient along with effective electrolyte replenishment by delivering both a laxative and electrolytes via a food item. The food item is prepared by either combining, mixing, or integrating the ingredients that form the food item together with one of or both of a laxative and electrolytes so that the ingredients in the food item either eliminate or significantly reduce the poor taste associated with either the electrolytes or the laxative. Eliminating or reducing the poor taste associated with either electrolytes or laxative, greatly improves patient satisfaction and compliance with ingesting these substances in order to, for example, prepare the GI tract of the patient for a medical or surgical procedure.

Abstract: Disclosed herein are shelf-stable, clear liquid nutritional compositions having a pH ranging from 2.5 to 4.6 and comprising water; at least one source of EGCg in an amount sufficient to provide 200-1700 mg/L of EGCg; and at least one source of protein in an amount sufficient to provide 25-45 g/L of total protein. The shelf-stable, clear liquid nutritional compositions lose no more than 20% by weight solids of the EGCg content present in the initial formulation of the compositions to epimerization, degradation, or both epimerization and degradation during heat sterilization. In certain embodiments, the loss of EGCg is exhibited by the amount of epimerization product GCg present in the shelf-stable, clear liquid nutritional composition following heat sterilization. Methods for preparing the shelf-stable, clear liquid nutritional compositions are also disclosed herein.

Abstract: An anti-oxidative Lactobacillus rhamnosus CCFM1107 can relieve chronic alcoholic liver injury, and L. rhamnosus CCFM1107 can be used in preparing dairy products as starter culture. The dairy products of this invention include milk, milk powder, milk capsules or fermented milk containing L. rhamnosus CCFM1107. It has strong abilities of anti-oxidation, scavenging diphenyl picrylhydrazyl (DPPH) radical and hydroxyl radical, inhibiting lipid peroxidation, tolerating cholate, chlorine sodium and pH, and can improve liver function and antioxidative index, lower serum endotoxin level and regulate intestinal flora distribution, thus effectively relieving alcoholic liver injury of mice.

Abstract: A solid supplement comprising the following components (A) and (B): (A) sphingomyelin in an amount of from 0.15 to 7% by mass; and (B) phosphatidyl inositol or a salt thereof, wherein the mass ratio of the content of phosphatidyl inositol or the salt thereof (B) in terms of phosphatidyl inositol content to the content of sphingomyelin (A) in the solid supplement, i.e., [(B)/(A)], is from 0.05 to 3.

Abstract: This invention relates to compositions that have utility, amongst others, in the stabilization of suspension particles or gas bubbles in fluid water-based compositions and/or in conferring shear thinning behavior to such fluid water-based compositions. The inventors have developed parenchymal cellulose based materials, which comprise cell wall derived networks of cellulose based fibers and nanofibrils, can advantageously be used for stabilization of suspended solid particles in fluid water-based compositions. Specific aspects of the invention concern the parenchymal cellulose based materials, their production and their use in fluid water-based compositions, as well as the resulting fluid water-based compositions per se.

Abstract: The present disclosure relates to compositions and methods that are effective in controlling and preventing bacterial, viral and fungal infections in the living tissue of plants, humans and animals, and in advancing the healing process for wounds to that tissue. The disclosed compositions comprise a biocidal system, a pH buffer, and one or more of a surfactant, a cellular energy supplement, an inflammation reducer, a clotting agent, an electrolytic system, a lattice forming system, and for plants a fungicide, all in an aqueous composition.

Abstract: The present invention encompasses combinations comprising a plurality of amino acids, formulations thereof for use in humans and animals, as well as methods for increasing muscle protein synthesis, muscle strength, and/or muscle function in a subject with chronic heart failure, cardiac cachexia or a combination thereof.

Abstract: This invention relates to use of glycerol-containing solutions for improving both the metabolic and hydration state of fasting individuals. The same solutions can be utilized in persons facing situations where urination is impossible or inconvenient.

Abstract: A pharmaceutical dosage form which comprises diphenhydramine and/or a pharmaceutically acceptable salt thereof and at least one second drug. The dosage form provides a plasma concentration within the therapeutic range of the at least one second drug over a period which is coextensive with a substantial part of the period over which the dosage form provides a plasma concentration within the therapeutic range of diphenhydramine or salt thereof. This Abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.

Abstract: The present disclosure relates to pharmaceutical compositions comprising omega-3 fatty acids and vitamin D for use in at least one of preventing and treating psoriasis, and to food supplement, dietary supplement, nutritional supplement, over-the-counter (OTC) supplement, medical food, or pharmaceutical grade supplement compositions comprising omega-3 fatty acids and vitamin D for use in improving at least one parameter associated with psoriasis.

Abstract: The invention described herein provides a preparation comprising a non-mammalian derived mixture of serine glycerophospholipid conjugates with a specific content and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and EPA which depend on utilizing different sources of lipids, and uses of such preparations.

Abstract: The invention described herein provides a preparation comprising a non-mammalian derived mixture of serine glycerophospholipid conjugates with a specific content and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and EPA which depend on utilizing different sources of lipids, and uses of such preparations.

Abstract: The present invention provides for microbial compositions and methods for reducing the concentration of short-chain fatty acids in the gut as a way to reduce energy uptake and manage obesity. More specifically, the invention provides for decreasing short-chain fatty acids available for absorption in the human gut, such as acetate, using one or more of: a probiotic including a homo-acetogenic, acetate oxidizing bacterium that converts acetate to H2; a probiotic including an acetoclastic methanogen; a microbial electrolysis cell comprising a homo-acetogenic bacterium and/or an acetoclastic methanogen; a prebiotic that enhances the growth or function of acetate-scavenging microbiota; or a highly selective antibiotic that targets H2-oxidizing methanogens.

Abstract: The present technology relates to a dietary supplement, composition, nutraceutical, and/or system for inducing or treating biological responses or conditions (namely sleep or sleep disorders) which utilize ultra-low dosage amounts of vitamins, minerals, amino acids, co-enzymes, stimulants, and/or similar ingredients in a highly bio-active delivery system which bypasses first pass metabolism. In particular, the present technology relates to a nutraceutical composition/formulation which substantially bypasses first pass metabolism and such as, but not limited to, sleep apnea. Methods of using the composition/formulation to elicit enhanced sleep quality, induce short duration sleep and/or treat sleep disorders are also provided.

Abstract: Dry stabilizing compositions for bioactive materials include sugars and hydrolyzed proteins, and may be formed into tablets or other forms providing enhanced stability for the bioactive material. Compositions containing the bioactive materials may be produced by a method that includes (a) combining the bioactive material with other ingredients in an aqueous solvent to form a viscous slurry; (b) snap-freezing the slurry in liquid nitrogen to form solid frozen particles, beads, droplets or strings; (c) primary drying by water removal under vacuum of the product of step (b) while maintaining it at a temperature above its freezing temperature; and (d) secondary drying of the product of step (c) at maximum vacuum and a temperature of 20° C. or higher for a time sufficient to reduce the water activity to below 0.3 Aw.

Abstract: The present invention relates to nutritional supplements to be administered to, or to be taken by, people who are subject, or thought to be subject to, iron deficiency anemia. The nutritional supplements of this invention have a unique formulation of iron and folic acid-related materials in addition to certain other vitamins and minerals and a nutritionally acceptable carrier therefor. The invention describes specific nutritional supplements for the use set forth above.